The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Replimune (REPL) shares climbed more than 60% in the premarket on Friday after the company announced plans to resubmit a marketing application for its lead asset RP1 in the U.S., following its second ...
Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...
The website for the popular JDownloader download manager was compromised earlier this week to distribute malicious Windows and Linux installers, with the Windows payload found deploying a Python-based ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Neutral-atom arrays are a rapidly emerging platform to create quantum computers. In a foundational study led by graduate students Aaron Holman and Yuan Xu from the Will and Yu labs, respectively, the ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject of discussion was Replimune's RP1, a cancer drug being trialed as a ...
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results